Alzaabi, AshrafAshrafAlzaabiBell, John PJohn PBellMontero-Arias, FeliciaFeliciaMontero-AriasPrice, David BDavid BPriceJackson, David JDavid JJacksonHAO-CHIEN WANGBudgen, NigelNigelBudgenFarouk, HishamHishamFaroukMaslova, EkaterinaEkaterinaMaslova2023-12-042023-12-042023-110741238Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/637495Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.enAsthma; Asthma control; Carbon footprint; Environmental monitoring; Greenhouse gas emissions; Inhaler therapies; Inhalers; SABA; Short-acting β2-agonist[SDGs]SDG3[SDGs]SDG8[SDGs]SDG10[SDGs]SDG12[SDGs]SDG13journal article10.1007/s12325-023-02663-2376844932-s2.0-85170205350https://api.elsevier.com/content/abstract/scopus_id/85170205350